1921
Volume 100, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Falsified and substandard medicines are associated with tens of thousands of deaths, mainly in young children in poor countries. Poor-quality drugs exact an annual economic toll of up to US$200 billion and contribute to the increasing peril of antimicrobial resistance. The WHO has emerged recently as the global leader in the battle against poor-quality drugs, and pharmaceutical companies have increased their roles in assuring the integrity of drug supply chains. Despite advances in drug quality surveillance and detection technology, more efforts are urgently required in research, policy, and field monitoring to halt the pandemic of bad drugs. In addition to strengthening international and national pharmaceutical governance, in part by national implementation of the Model Law on Medicines and Crime, a quantifiable Sustainable Development Goal target and an international convention to insure drug quality and safety are urgent priorities.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0981
2019-05-01
2019-05-27
Loading full text...

Full text loading...

/deliver/fulltext/14761645/100/5/tpmd180981.html?itemId=/content/journals/10.4269/ajtmh.18-0981&mimeType=html&fmt=ahah

References

  1. Renschler JP, Walters KM, Newton PN, Laxminarayan R, , 2015. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan African. Am J Trop Med Hyg 92: 119126. [Google Scholar]
  2. WHO, 2017. A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products. Geneva, Switzerland: World Health Organization . License: CC BY-NC-SA 3.0 IGO. [Google Scholar]
  3. Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, Herrington JE, , 2018. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Netw Open 1: e181662. [Google Scholar]
  4. WHO, 2017. WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products. Geneva, Switzerland: World Health organization . License: CC BY- NC-SA 3.0 IGO. Available at: http://www.who.int/medicines/regulation/ssffc/publications/GSMS_Report.pdf. Accessed September 18, 2018. [Google Scholar]
  5. Ozawa S, Evans DR, Higgins CR, Lang SK, Awor P, , 2019. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study. Malar J 18: 5. [Google Scholar]
  6. WHO, 2016. WHO Global Surveillance and Monitoring System SSFFC Medical Products. Technical Briefing. Available at: http://www.who.int/medicines/technical_briefing/tbs/TBS2016_SSFFC_Products.pdf. Accessed January 24, 2018. [Google Scholar]
  7. Newton PN, 2019. Oxford Statement. Available at: https://medswecantrust.org/Oxford-statement. Accessed February 15, 2019.
  8. WHO, 2016. Annual Report. WHO Essential Medicines and Health Products. Available at: http://www.who.int/medicines/publications/annual-reports/WHO_EMP_Report_2016_Online.pdf. Accessed September 20, 2018. [Google Scholar]
  9. WHO, 2017. Seventieth World Health Assembly Update, 29 May 2017. Available at: http://www.who.int/mediacentre/news/releases/2017/dementia-immunization-refuguees/en/. Accessed September 18, 2018. [Google Scholar]
  10. WHO, 2017. WHO Member State Mechanism on Substandard/Spurious/Falselylabelled/Falsified/Counterfeit (SSFFC) Medical Products. Available at: http://www.who.int/medicines/regulation/ssffc/A70_23-en1.pdf. Accessed September 18, 2018. [Google Scholar]
  11. WHO, 2017. A New Model for Regulatory System Strengthening. Available at: http://www.who.int/medicines/areas/quality_safety/regulation_legislation/rss_new-model/en/. Accessed September 20, 2018. [Google Scholar]
  12. International Association of Pharmaceutical Manufacturers and Associations (IFPMA), 2018. Falsified Medicines. Available at: https://www.ifpma.org/topics/falsified-medicines/. Accessed September 20, 2018. [Google Scholar]
  13. Mackey TK, Liang BA, York P, Kubic T, , 2015. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment. Am J Trop Med Hyg 92: 5967. [Google Scholar]
  14. Nayyar GML, Attaran A, Clark JP, Culzoni MJ, Fernandez FM, Herrington JE, Kendall M, Newton PN, Breman JG, , 2015. Responding to the pandemic of falsified medicines. Am J Trop Med Hyg 92: 113118. [Google Scholar]
  15. Nayyar GM, Breman JG, Newton PN, Herrington J, , 2012. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 12: 488496. [Google Scholar]
  16. Newton PN, Hanson K, Goodman C, ACTwatch Group; , 2017. Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries. Malar J 16: 204236. [Google Scholar]
  17. Newton PN, Green MD, Fernandez FM, , 2010. Impact of poor quality medicines in the developing world. Trends Pharmacol Sci 31: 99101. [Google Scholar]
  18. USP, 2017. Promoting the Quality of Medicines (PQM). Available at: http://www.usp-pqm.org/about. Accessed September 20, 2018. [Google Scholar]
  19. WWARN, 2018. Antimalarial Quality Surveyor. Available at: http://www.wwarn.org/aq-surveyor. Accessed September 20, 2018. [Google Scholar]
  20. Weinstein ZB, Zaman MH, , 2019. Evolution of Rifampin resistance in Escherichia coli and Mycobacterium smegmatis due to substandard drugs. Antimicrob Agents Chemother: e01243- 18. [Google Scholar]
  21. Davies J, Davies DO, , 2010. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74: 417433. [Google Scholar]
  22. Antignac M, Diop BI, Do B, N’Guetta R, Toure IA, Zabsonre P, Jouven X, , 2017. Quality assessment of 7 cardiovascular drugs in 10 sub-Saharan countries: the SEVEN study. JAMA Cardiol 2: 223225. [Google Scholar]
  23. WHO, 2017. Medical Product Alert N° 3/2017–Falsified Avastin (Bevacizumab) and Sutent (Sunitinib Malate) Circulating in East Africa. Available at: http://www.who.int/medicines/publications/drugalerts/drug_alert3-2017/en/. Accessed September 20, 2018. [Google Scholar]
  24. WHO, 2017. Medical Product Alert N° 4/2017–Falsified Penicillin V Circulating in Cameroon. Available at: http://www.who.int/medicines/publications/drugalerts/drug_alert4-2017/en/. Accessed September 20, 2018. [Google Scholar]
  25. WHO, 2017. Medical Product Alert N° 2/2016–Falsified AMARIL Yellow Fever Vaccines Circulating in South East Asia. Available at: http://www.who.int/medicines/publications/drugalerts/Alert2_2016_Fev_Falsified_AMARILyellow-fever-vaccine_searo_en.pdf. Accessed September 20, 2018. [Google Scholar]
  26. WHO, 2017. Medical Product Alert N° 1/2017–Falsified Meningococcal ACWY Vaccine Circulating in West Africa. Available at: http://www.who.int/medicines/publications/drugalerts/WHO_ALERTn1.2017_Falsified_meningitisVaccineNiger.pdf?ua=1. Accessed September 20, 2018. [Google Scholar]
  27. WHO, 2017. Antimicrobial Resistance. Available at: http://www.who.int/mediacentre/factsheets/fs194/en/. Accessed September 20, 2018. [Google Scholar]
  28. Gallagher JC, Colaizzi JL, , 2000. Issues in internet pharmacy practice. Ann Pharmacother 34: 14831485. [Google Scholar]
  29. CSIP, 2016. The Internet Pharmacy Market in 2016: Trends, Challenges, and Opportunities. Available at: https://safemedsonline.org/resource/the-internet-pharmacy-market-in-2016-trends-challenges-and-opportunities/. Accessed September 20, 2018. [Google Scholar]
  30. Mackey TK, Nayyar G, , 2016. Digital danger: a review of the global public health, patient safety and cybersecurity threats posed by illicit online pharmacies. Br Med Bull 118: 110126. [Google Scholar]
  31. FDA, 2017. FDA Conducts Major Global Operation to Protect Consumers from Potentially Dangerous Prescription Drugs Sold Online. FDA News Release; September 25, 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm577178.htm. Accessed September 20, 2018. [Google Scholar]
  32. FDA, 2017. Fact Sheet. Available at: https://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM553532.pdf. Accessed September 20, 2018. [Google Scholar]
  33. Preston C, Chahal HS, Porras A, Cargill L, Hinds M, Olowokure B, Cummings R, Hospedales J, , 2016. Regionalization as an approach to regulatory systems strengthening: a case study in CARICOM member states. Rev Panam Salud Publica 39: 262268. [Google Scholar]
  34. Strachan J, , 2017. Harmonization: Regulation Goes Global. Available at: https://themedicinemaker.com/issues/0917/harmonization-regulation-goes-global/. Accessed September 20, 2018. [Google Scholar]
  35. Seiter A, , 2012. Medicines Regulation, Regulatory Harmonization, Global Initiatives–Presentation. Available at: http://www.who.int/medicines/areas/policy/IPC_dec2012_Seiter_reg.pdf. Accessed September 18, 2018. [Google Scholar]
  36. Hajjou M, 2015. Monitoring the quality of medicines: results from Africa, Asia, and South America. Am J Trop Med Hyg 92: 6874. [Google Scholar]
  37. FDA, 2017. U.S. FDA International Programs. Available at: https://www.fda.gov/InternationalPrograms/. Accessed September 20, 2018. [Google Scholar]
  38. WHO, 2017. Strengthening Regulation of Medical Products in Bangladesh. Available at: http://www.searo.who.int/bangladesh/cipmeeting/en/. Accessed September 18, 2018. [Google Scholar]
  39. Liang BA, , 2008. Pigs, Drugs, and Terrorists. Available at: https://www.psqh.com/analysis/november-december-2008-health-policy/. Accessed September 20, 2018. [Google Scholar]
  40. Partnership for Safe Medicines, 2017. How Can Counterfeit Drugs Be Useful to Terrorists? Available at: http://www.safemedicines.org/counterfeit-drugs-and-terrorism. Accessed September 20, 2018. [Google Scholar]
  41. Attaran A, , 2015. Stopping murder by medicine: introducing the model law on medicine crime. Am J Trop Med Hyg 92: 127132. [Google Scholar]
  42. Attaran Amir, . Model Law on Medicine Crime (April 15, 2015). Available at: https://ssrn.com/abstract:2530087 or http://dx.dpi.org/10.2139/SSM.2530087. Accessed February 16, 2019.
  43. Kovacs S, Hawes SE, Maley SN, Mosites E, Wong L, Stergachis A, , 2014. Technologies for detecting falsified and substandard drugs in low and middle-income countries. PLoS One 9: e90601. [Google Scholar]
  44. Taylor D, , 2014. RFID in the pharmaceutical industry: addressing counterfeits with technology. J Med Syst 38: 141. [Google Scholar]
  45. Mackey TK, Nayyar GA, , 2017. Review of existing and emerging digital technologies to combat the global fake medicines trade. Expert Opin Drug Safe 16: 587602. [Google Scholar]
  46. Marr B, , 2016. How Blockchain Technology Could Change the World. Available at: http://www.forbes.com/sites/bernardmarr/2016/05/27/how-blockchain-technology-could-change-the-world/. Accessed September 18, 2018. [Google Scholar]
  47. IOM Buckley GJ, Gostin LO, ; , 2013. Countering the Problem of Falsified and Substandard Drugs. Washington, DC: National Academies Press. [Google Scholar]
  48. UN, 2015. Sustainable Development Goals. Available at: https://sustainabledevelopment.un.org/sdgs. Accessed September 18, 2018. [Google Scholar]
  49. Nayyar GML, Breman JG, Herrington JE, , 2015. The global pandemic of falsified medicines: laboratory and field innovations and policy perspectives. Am J Trop Med Hyg 92: 27. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0981
Loading
/content/journals/10.4269/ajtmh.18-0981
Loading

Data & Media loading...

  • Received : 10 Dec 2018
  • Accepted : 27 Jan 2019
  • Published online : 01 May 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error